NasdaqGM:OCULPharmaceuticals
Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?
Ocular Therapeutix, Inc. recently reported first-quarter 2026 results, with revenue of US$10.79 million, slightly above the prior-year period, alongside a wider net loss of US$88.61 million and basic and diluted loss per share of US$0.40.
The combination of almost flat revenue and a meaningfully larger quarterly net loss highlights the company’s ongoing investment burden as it advances its ophthalmology pipeline.
With first-quarter results showing a wider net loss despite stable revenue,...